# ESCMID 2025 vs HIV PEP Pro

The clearest difference is price: ESCMID 2025 at Free against HIV PEP Pro's $1.99. ESCMID 2025 also leads on iOS requirement (14.0 vs 26.0). HIV PEP Pro's advantage is update cadence (weekly vs fortnightly). On ads, in-app purchases and device support there is nothing between them.

ESCMID 2025 is free to download; HIV PEP Pro costs $1.99 up front. Neither carries in-app purchases, so what you see is what you pay.

ESCMID 2025 ships an update fortnightly, HIV PEP Pro weekly. The most recent releases landed on September 22, 2026 and November 9, 2026 respectively.

## The numbers

| Metric | ESCMID 2025 | HIV PEP Pro |
| --- | --- | --- |
| Price | **Free** | $1.99 |
| In-app purchases | No | No |
| Ads | No | No |
| Update frequency | Fortnightly | **Weekly** |
| Size | 88 MB | 17 MB |
| Requires iOS | **14.0** | 26.0 |
| Devices | **iPhone, iPad, iPod** | iPhone, iPad |
| Age rating | 17+ | 4+ |
| Developer | [key4events](https://appshunter.io/developer/490630030) | [Mohammed Rashid](https://appshunter.io/developer/1864598715) |

## What reviewers say

### ESCMID 2025

[App page](https://appshunter.io/ios/app/escmid-2025/id6738580239)

**Features:** macOS Compatibility

**In-app purchases:** none


### HIV PEP Pro

[App page](https://appshunter.io/ios/app/hiv-pep-pro/id6757250909)

**Features:** macOS Compatibility

**In-app purchases:** none


## Frequently asked questions

### Is ESCMID 2025 free?

ESCMID 2025 is free to download, with no in-app purchases.

### Is HIV PEP Pro free?

HIV PEP Pro costs $1.99, with no in-app purchases.

### Do ESCMID 2025 or HIV PEP Pro have ads?

Neither ESCMID 2025 nor HIV PEP Pro shows ads.

### Which is updated more often, ESCMID 2025 or HIV PEP Pro?

ESCMID 2025 ships an update fortnightly, and HIV PEP Pro weekly. Most recently, ESCMID 2025 was updated on September 22, 2026 and HIV PEP Pro on November 9, 2026.

---

*Compared by [AppsHunter](https://appshunter.io/) from daily US App Store data. Review summaries are generated from verbatim App Store reviews.*
